10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2010 | |||
STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 17, 2011) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Cash flows from operating activities | |||
| Net loss | $ (104,468) | (67,830) | (79,129) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | |||
| Depreciation and amortization | 19,687 | 14,247 | 11,287 |
| Non-cash compensation expense | 39,897 | 31,259 | 32,523 |
| Loss on early extinguishment of debt | 0 | 0 | 938 |
| Net realized loss (gain) on marketable securities | 293 | (56) | 1,310 |
| Changes in assets and liabilities | |||
| Increase in accounts receivable | (27,544) | (30,356) | (16,892) |
| Decrease (increase) in prepaid expenses and other assets | 2,723 | (4,574) | (6,560) |
| Increase (decrease) in deferred revenue | 158,151 | (27,497) | (26,834) |
| Increase (decrease) in accounts payable, accrued expenses, and other liabilities | 7,605 | 12,577 | (5,729) |
| Total adjustments | 200,812 | (4,400) | (9,957) |
| Net cash provided by (used in) operating activities | 96,344 | (72,230) | (89,086) |
| Cash flows from investing activities | |||
| Purchases of marketable securities | (605,124) | (199,997) | (581,139) |
| Sales or maturities of marketable securities | 276,601 | 297,411 | 646,861 |
| Purchases of restricted marketable securities | (7,063) | 0 | 0 |
| Decrease (increase) in restricted cash | 1,122 | 50 | (50) |
| Capital expenditures | (99,689) | (97,318) | (34,857) |
| Net cash (used in) provided by investing activities | (434,153) | 146 | 30,815 |
| Cash flows from financing activities | |||
| Repurchases or repayment of notes payable | 0 | 0 | (200,807) |
| Proceeds in connection with facility lease obligation | 47,544 | 23,640 | 0 |
| Payments in connection with facility lease obligation | (924) | (875) | 0 |
| Net proceeds from the issuance of Common Stock | 196,790 | 8,598 | 7,949 |
| Payments in connection with capital lease obligation | (104) | 0 | 0 |
| Net cash provided by (used in) financing activities | 243,306 | 31,363 | (192,858) |
| Net decrease in cash and cash equivalents | (94,503) | (40,721) | (251,129) |
| Cash and cash equivalents at beginning of period | 207,075 | 247,796 | |
| Cash and cash equivalents at end of period | 112,572 | 207,075 | 247,796 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | 12,737 | 2,525 | 9,348 |
| Cash paid for income taxes | 0 | 0 | 3,079 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |